D-Wave Quantum: A Quantum Computing Story of Contradictions

D-Wave faces securities probes and CFO exit, yet insurer adds stake. Bookings surge 1,120%, but losses widen and cash drops 33%.

The same week a law firm opened a fresh investigation into D-Wave Quantum's executive departures, an insurance giant quietly added to its stake in the company. On September 1, Pomerantz LLP announced it was probing potential securities fraud or other unlawful practices tied to the CFO's resignation — while The Manufacturers Life Insurance Company reported acquiring additional D-Wave shares on that very day. One party smells misconduct; another is increasing its exposure.

That tension captures the broader schizophrenia surrounding the quantum computing sector in autumn 2026. An industry once dismissed as pure laboratory research is now being measured by the full toolkit of conventional capital markets: trial lawyers circling for litigation opportunities, institutional investors building positions, and analysts slapping price targets well above current trading levels.

The stock itself sits at €14.60, up 2.0 percent in today's session — but that figure masks a twelve-month journey between euphoria and disillusionment.

A Tale of Two Narratives in the Numbers

D-Wave's second-quarter 2026 results offer ammunition for both bulls and bears. The optimists point to bookings: first-half 2026 orders reached $35.5 million, a 1,120 percent surge year-over-year, powered largely by a $20 million contract from Florida Atlantic University. Remaining performance obligations jumped 668 percent to $40.7 million, with more than half of that sum expected to convert into recognized revenue within the next twelve months.

The skeptics, however, look at actual revenue: Q2 came in at $3.1 million, essentially flat against the prior year and missing analyst estimates by 24 percent. And the truly concerned focus on profitability — adjusted EBITDA losses widened 85 percent to $37.1 million as the company poured money into product development and sales.

That gap between booking growth and loss expansion is the real test for this stock, not any single quarterly figure.

The Cash Question Looms Larger

Investors tracking liquidity have reason for vigilance. As of June 30, D-Wave held $546.2 million in cash and securities — down 33 percent from a year earlier, largely reflecting the $250 million cash component of the Quantum Circuits Inc. acquisition. That January 2026 deal, valued at $550 million in total, was meant to give D-Wave access to a second quantum computing architecture and cement its position as a dual-platform provider.

Strategically defensible, perhaps. Financially, it has meaningfully depleted the company's war chest — and with tens of millions in quarterly losses continuing, the runway question grows more pressing.

There is at least one encouraging shift: commercial customers now account for 62.4 percent of quarterly revenue, up from 45.1 percent a year ago. Global enterprises are gradually displacing pure research institutions in the client base, suggesting quantum computing is inching from laboratory curiosity toward commercial viability.

Management reaffirmed its guidance of two system deliveries for 2026, with the fourth quarter expected to deliver the bulk of annual revenue — a concentration that raises execution risk considerably.

Legal Scrutiny Meets Institutional Conviction

Multiple law firms are now examining potential securities violations at D-Wave, though the Pomerantz probe announced September 1 is notable for explicitly citing the circumstances of the CFO's departure. Such investigations are almost routine in the United States following share-price declines or unexpected executive changes — they don't necessarily culminate in litigation, but they signal that attorneys see vulnerabilities worth exploring. For shareholders, that translates to uncertainty rather than certainty.

The contrast with Manufacturers Life's concurrent share purchase is striking. Whether the insurer's move represents a bet on D-Wave's long-term fundamentals or simple portfolio rebalancing without deeper significance — both interpretations remain plausible — it illustrates how differently market participants weigh identical facts.

The stock has more than halved since its 52-week high of €40.41 in October of last year, now sitting 64 percent below that peak. That was the era when quantum computing was being celebrated as the next transformative technology trend. A more sober reading has since taken hold: missed revenue expectations in Q2, a CFO transition, and now legal inquiries.

Yet the shares have climbed meaningfully off their March 30 low of €11.12, suggesting the selling pressure may be easing even as fundamental questions persist.

External Validation, Market Caution

D-Wave's reputation has its defenders. In August 2026, the company was one of only two firms placed in the Leaders category of the IDC MarketScape for quantum computing. It also received $1.57 million from the US National Science Foundation for a research project called ERASE. Such accolades and grants underscore the technological positioning — but they don't pay the bills.

The capital markets have grown more circumspect. Zacks Research downgraded the stock from "Strong Buy" to "Hold" on August 21 — a signal of growing valuation caution, even if automated rating systems warrant skeptical interpretation. BMO Capital Markets had initiated coverage with an Outperform rating and a $35 price target on August 24, but that call predates both the CFO departure and the subsequent legal scrutiny, leaving its relevance in question.

The CFO transition and the board appointment of Kevan P. Krysler have already demonstrated the nervousness of recent weeks. The stock trades at €14.45, only modestly above its 52-week trough — evidence that the market is discounting the growth story considerably.

For investors, D-Wave has become a case study in how technological promise and near-term governance concerns can collide — a pattern likely to repeat as the young quantum computing industry matures. The bookings growth is real and impressive, but it has yet to translate into revenue while losses outpace earnings. The Quantum Circuits acquisition has visibly thinned the cash reserves, and concentrating the annual forecast into a single quarter leaves little margin for disappointment. Those betting on long-term quantum commercialization will find substance here; those seeking near-term stability will likely look elsewhere.